expression of receptor tyrosine kinase ror1 in a wide variety of cancers has emerged as a new era focusing on targeting this receptor in cancer therapy. our preliminary re-sults indicate the presence of a truncated transcript of ror1 in tumor cells. the trun-cated ror1 encompasses extracellular and transmembrane domains, lacking catalytic kinase domain (ror1-ecd). as enzyme activity is highly d...

objective: prostate cancer is one of the most common cancer in the developed countries. most of cancer deaths are due to development of metastasis. hence, prevention of metastasis is critical. silibinin is a flavonoid component that inhibits cell proliferation and causes cell death of human prostate cancer. in this study, the expression of cd82 gene in pc-3 cells treated with escalating concent...

The identification of potentially useful immune-based treatments for prostate cancer has been severely constrained by the scarcity of relevant animal research models for this disease. Moreover, some of the most critical mechanisms involved in complete and proper antitumoral T cell activation have only recently been identified for experimental manipulation, namely, components involved in the cos...

Prostate cancer is the second highest cause of male cancer deaths in the United States. A significant number of tumors advance to a highly invasive and metastatic stage, which is typically resistant to traditional cancer therapeutics. In order to identify chromosomal structural variants that may contribute to prostate cancer progression we sequenced the genomes of a HPV-18 immortalized nonmalig...

there exists an association between pi3k pathway licentious activity and the considerable feature of high metastatic potential of the genitourinary cancer cells. although du 145 and 5637 have functional phosphatase and tensin homolog (pten) tumor suppressor gene, which antagonizes pi3k function, pc-3 is null for pten gene. in pursuit to explain why pten bearing cell lines display high metastati...

Responses to androgen vary widely among prostate cancers and prostatic carcinoma cell lines. We have explored the basis for this heterogeneity by examining the levels of androgen receptor expression in a prostate carcinoma cell line (LNCaP) that expresses the androgen receptor and two prostate carcinoma cell lines that do not contain detectable androgen receptor. We find that while the LNCaP ce...

Responses to androgen vary widely among prostate cancers and prostatic carcinoma cell lines. We have explored the basis for this heteroge neity by examining the levels of androgen receptor expression in a prostate carcinoma cell line (LNCaP) that expresses the androgen recep tor and two prostate carcinoma cell lines that do not contain detectable androgen receptor. We find that while the LNCaP ...

Responses to androgen vary widely among prostate cancers and prostatic carcinoma cell lines. We have explored the basis for this heteroge neity by examining the levels of androgen receptor expression in a prostate carcinoma cell line (LNCaP) that expresses the androgen recep tor and two prostate carcinoma cell lines that do not contain detectable androgen receptor. We find that while the LNCaP ...

The fate of circulating tumor cells is an important determinant of their ability to form distant metastasis. Here, we demonstrate the use of in vivo flow cytometry as a powerful new method for detecting quantitatively circulating cancer cells. We specifically examine the circulation kinetics of two prostate cancer cell lines with different metastatic potential in mice and rats. We find that the...

The fate of circulating tumor cells is an important determinant of their ability to form distant metastasis. Here, we demonstrate the use of in vivo flow cytometry as a powerful new method for detecting quantitatively circulating cancer cells. We specifically examine the circulation kinetics of two prostate cancer cell lines with different metastatic potential in mice and rats. We find that the...